Recent News for HROW - Harrow Health, Inc.

Date Title
Aug 19 Harrow Health Enters Oversold Territory
Aug 15 SHAREHOLDER ALERT: Investigation of Harrow Health Announced by Holzer & Holzer, LLC
Aug 15 Harrow Health down 22% after Q2 report absent a key disclosure
Aug 15 Microcaps mostly among midday movers
Aug 15 Does Harrow Health, Inc.'s (NASDAQ:HROW) CEO Pay Matter?
Aug 15 Sintx Technologies leads healthcare gainers; Cytosorbents and Genetic Technologies among losers
Aug 14 Harrow Health, Inc. (HROW) CEO Mark Baum on Q2 2019 Results - Earnings Call Transcript
Aug 14 Harrow Health (HROW) Reports Q2 Loss, Tops Revenue Estimates
Aug 14 Harrow Health EPS misses by $0.02, beats on revenue
Aug 14 Harrow Health Announces Second Quarter 2019 Results
Aug 7 Analysts Estimate Harrow Health (HROW) to Report a Decline in Earnings: What to Look Out for
Aug 2 Harrow Health nabs rights to microbial agent for eye and ear infections
Aug 2 Harrow Health Forms Stowe Pharmaceuticals Subsidiary to Develop Broad Spectrum Anti-Microbial Ophthalmic and Otic Therapeutics
Jul 31 Harrow Health Announces Launch of Mayfield Pharmaceuticals
Jul 31 28 Healthcare Stocks Moving In Tuesday's After-Market Session
Jul 25 Harrow Health to Announce Second Quarter 2019 Financial Results on August 14, 2019
Jul 10 Do Insiders Own Shares In Harrow Health, Inc. (NASDAQ:HROW)?
Jul 1 Aclaris Therapeutics and Precipio among healthcare gainers; Evofem Biosciences leads the losers
Jun 25 Amid Bay Area exodus, Nashville is rockin’
Jun 25 Harrow Health Adds Two Senior Executives to its Nashville Team
Jun 19 The city's newest public company wants to build a new industry in Nashville
Jun 18 Harrow Health, Inc to Locate Headquarters in Nashville, Tennessee
Jun 18 Publicly traded San Diego firm moving HQ to Nashville
May 31 Harrow Health, Inc. Is Quickly Taking Over The Ophthalmology Pharmaceutical Market
May 30 Novel Drug Solutions, LLC and Eye Care Northwest, PA Terminates Agreement with Harrow Health, Inc.
Back to the Main HROW Page...